{
    "popularityCurve": {
        "data": [
            5
        ],
        "xLabels": [
            "04:13"
        ],
        "label": "we are very pleased to announce that the fda has issued an approvable letter for stavzor and we offer our congratulations to the banner and jds teams for this successful result"
    },
    "clusterList": [
        {
            "phrase": "we are very pleased to announce that the fda has issued an approvable letter for stavzor and we offer our congratulations to the banner and jds teams for this successful result",
            "count": 1
        },
        {
            "phrase": "the small size and soft gel capsule formulation of stavzor should make this new product easy to swallow which in my experience is critical to helping valproate patients start and stay on their medication",
            "count": 1
        },
        {
            "phrase": "our research indicates that valproate patients would prefer a small soft gel capsule like stavzor that is easy to swallow",
            "count": 1
        },
        {
            "phrase": "in a recent survey of 400 valproate users more than two-thirds reported difficulty swallowing their other valproate medications and 85 percent said they would have preferred a small soft gel capsule had it been available when initiating therapy these are some of the patients who we expect to help with the launch of stavzor",
            "count": 1
        },
        {
            "phrase": "for patients it represents a new easy-to-swallow treatment option that may help with compliance for noven it represents a significant step toward our goal of establishing noven as a high-growth specialty pharmaceutical company",
            "count": 1
        }
    ]
}